Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this 45-minute activity, medical oncologists Sara Hurvitz, MD, and Hope Rugo, MD, discuss key concepts in integrating these evidence-based advancements into clinical practice. They share their thoughts about selecting personalized treatment based on biomarkers, utilizing liquid biopsy techniques to guide therapy for ET resistance, and applying the latest evidence to overcome ET resistance and optimize patient outcomes.
This content is also availble as a podcast: You may listen here.
Please visit our related course, Interprofessional Care of Patients with HR+/HER2− Metastatic Breast Cancer, by clicking here.
Course Credit:
1.00 AMA PRA Category 1 CreditTM
Dates:
Opens: 2025-04-10
Closes: 2026-04-10
Target Audience:
This activity is intended for community-and institution-based medical oncologists, pathologists, and other oncology healthcare providers such as nurse practitioners, physician associates, nurses, and pharmacists.
This activity is supported by an independent educational grant from Lilly.
-
Sara A. Hurvitz, MD
Professor of Medicine
Smith Family Endowed Chair in Women’s Health
Head, Division of Hematology and Oncology | Senior Vice President, Clinical Research Division
Department of Medicine, UW Medicine | Fred Hutchinson Cancer Center
Seattle, Washington -
Hope S. Rugo, MD
Professor of Medicine
Winterhof Family Distinguished Professor of Breast Oncology
University of California San Francisco Comprehensive Cancer Center
San Francisco, California
